Cargando…

Innovative Approach for a Typology of Treatment Sequences in Early Stage HER2 Positive Breast Cancer Patients Treated With Trastuzumab in the French National Hospital Database

BACKGROUND: Our objective was to describe the hospital-based systemic treatment sequences in early stage HER2+ breast cancer patients treated with trastuzumab in France in 2016. METHODS: This retrospective observational study was based on the national hospital discharge database (PMSI). Patients hos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tredan, Olivier, Laurent, Marie, Gilberg, Melina, Ghorbal, Rim, Vainchtock, Alexandre, Lortet-Tieulent, Joannie, Prodel, Martin, Dupin, Julien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661546/ https://www.ncbi.nlm.nih.gov/pubmed/36386278 http://dx.doi.org/10.1177/11769351221135134

Ejemplares similares

Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab
por: Chouaïd, Christos, et al.
Publicado: (2022)

Thyroid cancer “epidemic” also occurs in low‐ and middle‐income countries
por: Lortet‐Tieulent, Joannie, et al.
Publicado: (2018)

Costs and mortality associated with HIV: a machine learning analysis of the French national health insurance database
por: Prodel, Martin, et al.
Publicado: (2021)

Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer
por: Soerjomataram, Isabelle, et al.
Publicado: (2012)

Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study
por: Fauchier, Laurent, et al.
Publicado: (2015)

Capturing farm diversity with hypothesis-based typologies: An innovative methodological framework for farming system typology development
por: Alvarez, Stéphanie, et al.
Publicado: (2018)

Eco-Innovation and Innovation Level of the Economy as a Basis for the Typology of the EU Countries
por: Sobczak, Elżbieta, et al.
Publicado: (2022)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012)

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients
por: Jobard, Elodie, et al.
Publicado: (2017)

Potential estimation model in French alpine skiing - Individual evolution curve and progression typology
por: De Larochelambert, Quentin, et al.
Publicado: (2023)

Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERmione non-interventional prospective study
por: Jacquin, Jean-Philippe, et al.
Publicado: (2019)

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study
por: Scherpereel, Arnaud, et al.
Publicado: (2018)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis
por: Girard, Nicolas, et al.
Publicado: (2018)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Innovative public library services during the COVID-19 pandemic: Application and revision of social innovation typology
por: Syn, Sue Yeon, et al.
Publicado: (2023)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
por: Moinard-Butot, Fabien, et al.
Publicado: (2022)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Hospital costs of Balloon Pulmonary Angioplasty (BPA) procedure and management for CTEPH patients: An observational study based on the French national hospital discharge database (PMSI)
por: Cottin, Vincent, et al.
Publicado: (2021)

Crisis-driven innovation and fundamental human needs: A typological framework of rapid-response COVID-19 innovations
por: Dahlke, Johannes, et al.
Publicado: (2021)

Linguistic typology
por: Ramat, Paolo
Publicado: (1987)

Phylogenetic Typology
por: Jäger, Gerhard, et al.
Publicado: (2021)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
por: Maadi, Hamid, et al.
Publicado: (2018)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
por: Li, Xin, et al.
Publicado: (2018)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
por: Burguin, Anna, et al.
Publicado: (2020)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
por: Fiszman, Gabriel L., et al.
Publicado: (2011)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators
por: Scheer, Justin M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_put48r3j8jrpd6ge98dir7pcff